Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 7:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,537 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Health Impairment Clear all
Recruiting Not applicable Interventional

IHT for Mild Cognitive Impairment

NCT05495087
View directory record Official record
Conditions
Mild Cognitive Impairment, Memory Impairment
Interventions
IHT Treatment, Sham-IHT Control
Device · Other
Lead sponsor
University of North Texas Health Science Center
Other
Eligibility
55 Years to 79 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 3, 2026, 7:08 PM EDT
Completed No phase listed Observational

Impact of Swallowing Impairment on Individuals With Parkinson Disease

NCT04769843
View directory record Official record
Conditions
Parkinson Disease, Dysphagia
Interventions
Not listed
Lead sponsor
Northern Arizona University
Other
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Flagstaff, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Sep 3, 2026, 7:08 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment

NCT02809118
View directory record Official record
Conditions
Hearing Loss, Idiopathic Sudden Sensorineural
Interventions
AM-111 0.4 mg/ml, AM-111 0.8 mg/ml, Placebo
Drug · Other
Lead sponsor
Auris Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
38
States / cities
Birmingham, Alabama • Escondido, California • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Sep 3, 2026, 7:08 PM EDT
Recruiting Phase 2 Interventional

Cognitive Training and Neuroplasticity in Mild Cognitive Impairment: COGIT-2 Trial

NCT06601933
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Cognitive Training
Interventions
Cognitive Training
Other
Lead sponsor
Columbia University
Other
Eligibility
55 Years to 89 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
4
States / cities
Miami, Florida • New York, New York • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function

NCT06916078
View directory record Official record
Conditions
Liver Dysfunction, Healthy
Interventions
Lepodisiran
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 3, 2026, 7:08 PM EDT
Terminated Phase 2 Interventional Results available

Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease

NCT02322021
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Alzheimer Type
Interventions
E2609, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
21
States / cities
Bellflower, California • Costa Mesa, California • Glendale, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 3, 2026, 7:08 PM EDT
Terminated Phase 4 Interventional Results available

Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography

NCT00209417
View directory record Official record
Conditions
Renal Insufficiency, Diabetes Mellitus
Interventions
Iodixanol 320-Arm 1, Iopamidol 300-Arm 2
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Rhythmic Light Therapy for Alzheimer's Disease Patients

NCT05015478
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Tailored Rhythmic Lighting Intervention, Placebo Rhythmic Lighting Intervention
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Menands, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 3, 2026, 7:08 PM EDT
Completed No phase listed Observational

Diaphragm Pacing After Spinal Cord Injury

NCT02556125
View directory record Official record
Conditions
Injuries, Spinal Cord
Interventions
Diaphragm pacing
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Sep 3, 2026, 7:08 PM EDT
Completed No phase listed Observational Results available

Evaluation of Veteran-Directed Home and Community Based Services

NCT03145818
View directory record Official record
Conditions
Functional Impairment, Caregiving
Interventions
VD-HCBS
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Durham, North Carolina • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment

NCT03114540
View directory record Official record
Conditions
Hepatic Impairment
Interventions
GBT440
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Sep 3, 2026, 7:08 PM EDT
Completed No phase listed Observational

Amyloid Beta and Cognition in Parkinson Disease

NCT01754168
View directory record Official record
Conditions
Parkinson Disease, Neurological Disorders
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
65 Years to 99 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Phase 3 Interventional Results available

Melatonin Intervention For Neurocognitive Deficits in the St. Jude Lifetime Cohort

NCT01700959
View directory record Official record
Conditions
Cancer Malignancies
Interventions
melatonin, placebo
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
911 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Phenytoin for Memory Impairment Secondary to Megestrol

NCT02595723
View directory record Official record
Conditions
Cognitive Impairment
Interventions
Phenytoin 200 mg capsule, Megestrol 800 mg liquid, Phenytoin-matched Placebo capsule, Megestrol-matched liquid Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2019 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Phase 4 Interventional Results available

Clinical Trial of Lamotrigine to Reverse Cognitive Impairment in Chronic Corticosteroid-Treated Patients

NCT00223262
View directory record Official record
Conditions
Memory Impairment Due to Corticosteroid Use, Hypomania Due to Corticosteroid Use, Hippocampal Atrophy Due to Corticosteroid
Interventions
Lamotrigine (Drug)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Timeline
2002 – 2005
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 3, 2026, 7:08 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Assessment of the Pharmacokinetics of GSK1278863 and Metabolites in Normal Subjects and Subjects With Renal Impairment

NCT01406340
View directory record Official record
Conditions
Anaemia
Interventions
5 mg GSK1278863
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects

NCT03742882
View directory record Official record
Conditions
Hepatic Impairment
Interventions
CC-90001
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Phase 3 Interventional

Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)

NCT00000174
View directory record Official record
Conditions
Alzheimer Disease, Cognition Disorders
Interventions
Rivastigmine
Drug
Lead sponsor
Novartis
Industry
Eligibility
55 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
15
States / cities
Peoria, Arizona • Orange, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Estrogen and Serotonin on Changing Brain Chemistry

NCT01208324
View directory record Official record
Conditions
Menopause
Interventions
estrogen patch, Amino acids, Placebo Patch, Placebo pills
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
48 Years to 60 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Audiobooks for Hearing Loss App as Auditory Training

NCT04231396
View directory record Official record
Conditions
Hearing Loss, Hearing Impaired Children, Hearing Impairment
Interventions
Audiobooks for hearing loss App
Other
Lead sponsor
BioSpeech
Industry
Eligibility
9 Years to 90 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Sep 3, 2026, 7:08 PM EDT
Not listed No phase listed Observational

Cognition and the Immunology of Postoperative Outcomes

NCT04792983
View directory record Official record
Conditions
Cognitive Impairment, Frail Elderly Syndrome, Delirium, Surgery
Interventions
No intervention
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Sep 3, 2026, 7:08 PM EDT
Not listed Phase 2 Interventional

Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder

NCT01466205
View directory record Official record
Conditions
Cognitive Impairments, Schizotypal Personality Disorder
Interventions
DAR-0100A, Placebo
Drug
Lead sponsor
Larry J. Siever
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Sep 3, 2026, 7:08 PM EDT
Enrolling by invitation Not applicable Interventional

Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device

NCT07222605
View directory record Official record
Conditions
Alzheimer Disease, Parkinson Disease, Frontotemporal Dementia, Cortico Basal Degeneration, Posterior Cortical Atrophy (PCA), Neurological Diseases or Conditions, Dementia
Interventions
MemorEM
Device
Lead sponsor
eQ8Health Corporation d/b/a CareONE Concierge
Industry
Eligibility
45 Years to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 3, 2026, 7:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects

NCT01493869
View directory record Official record
Conditions
Healthy, Hepatic Impairment
Interventions
cabozantinib
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2014 · Synced Sep 3, 2026, 7:08 PM EDT